JSPR Stock Overview
Jasper Therapeutics, Inc., a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies.
Jasper Therapeutics Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$3.13|
|52 Week High||US$18.88|
|52 Week Low||US$2.45|
|1 Month Change||23.72%|
|3 Month Change||-17.96%|
|1 Year Change||-68.45%|
|3 Year Change||n/a|
|5 Year Change||n/a|
|Change since IPO||-68.13%|
Recent News & Updates
|JSPR||US Biotechs||US Market|
Return vs Industry: JSPR underperformed the US Biotechs industry which returned -21.4% over the past year.
Return vs Market: JSPR underperformed the US Market which returned -12.3% over the past year.
|JSPR Average Weekly Movement||13.9%|
|Biotechs Industry Average Movement||12.4%|
|Market Average Movement||7.8%|
|10% most volatile stocks in US Market||16.8%|
|10% least volatile stocks in US Market||2.9%|
Stable Share Price: JSPR is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 14% a week.
Volatility Over Time: JSPR's weekly volatility has decreased from 21% to 14% over the past year, but is still higher than 75% of US stocks.
About the Company
Jasper Therapeutics, Inc., a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. It focuses on the development and commercialization of conditioning agents and stem cell engineering to allow expanded use of stem cell transplantation and ex vivo gene therapy, a technique in which genetic manipulation of cells is performed outside the body prior to transplantation. The company’s lead product candidate is JSP191, which is in clinical development as a conditioning antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.
Jasper Therapeutics Fundamentals Summary
|JSPR fundamental statistics|
Is JSPR overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|JSPR income statement (TTM)|
|Cost of Revenue||US$0|
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
|Earnings per share (EPS)||-0.61|
|Net Profit Margin||0.00%|
How did JSPR perform over the long term?See historical performance and comparison
Is Jasper Therapeutics undervalued compared to its fair value and its price relative to the market?
Valuation Score 0/6
Below Fair Value
Significantly Below Fair Value
PE vs Industry
PE vs Market
PB vs Industry
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate JSPR's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate JSPR's fair value for valuation analysis.
Price To Earnings Ratio
PE vs Industry: JSPR is unprofitable, so we can't compare its Price-To-Earnings Ratio to the US Biotechs industry average.
PE vs Market: JSPR is unprofitable, so we can't compare its Price-To-Earnings Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate JSPR's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: JSPR is overvalued based on its Price-To-Book Ratio (1.7x) compared to the US Biotechs industry average (1.5x).
How is Jasper Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?
Future Growth Score0/6
Future Growth Score 0/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: JSPR is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: JSPR is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: JSPR is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: JSPR is forecast to have no revenue next year.
High Growth Revenue: JSPR is forecast to have no revenue next year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: JSPR is forecast to be unprofitable in 3 years.
How has Jasper Therapeutics performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Last years earnings growth
Earnings and Revenue History
Quality Earnings: JSPR is currently unprofitable.
Growing Profit Margin: JSPR is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if JSPR's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare JSPR's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: JSPR is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (96.9%).
Return on Equity
High ROE: JSPR has a negative Return on Equity (-33.9%), as it is currently unprofitable.
How is Jasper Therapeutics's financial position?
Financial Health Score6/6
Financial Health Score 6/6
Short Term Liabilities
Long Term Liabilities
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: JSPR's short term assets ($73.8M) exceed its short term liabilities ($6.0M).
Long Term Liabilities: JSPR's short term assets ($73.8M) exceed its long term liabilities ($6.5M).
Debt to Equity History and Analysis
Debt Level: JSPR is debt free.
Reducing Debt: JSPR has not had any debt for past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: JSPR has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: JSPR has sufficient cash runway for 1.4 years if free cash flow continues to reduce at historical rates of 68.4% each year.
What is Jasper Therapeutics's current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Future Dividend Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate JSPR's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate JSPR's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if JSPR's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if JSPR's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as JSPR has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Ron Martell (59 yo)
Mr. Ronald A. Martell, also known as Ron, serves as President, Chief Executive Officer & Director at Jasper Therapeutics since March 15, 2022. He has been the President, Chief Executive Officer, Chief Fina...
Experienced Management: JSPR's management team is not considered experienced ( 1.9 years average tenure), which suggests a new team.
Experienced Board: JSPR's board of directors are not considered experienced ( 2.5 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Insufficient data to determine if shareholders have been diluted in the past year.
Jasper Therapeutics, Inc.'s employee growth, exchange listings and data sources
- Name: Jasper Therapeutics, Inc.
- Ticker: JSPR
- Exchange: NasdaqCM
- Founded: NaN
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: US$118.553m
- Shares outstanding: 37.88m
- Website: https://jaspertherapeutics.com
Number of Employees
- Jasper Therapeutics, Inc.
- 2200 Bridge Pkwy
- Suite 102
- Redwood City
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/05/24 00:00|
|End of Day Share Price||2022/05/24 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.